Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children (Two Age Groups: 1-<2 and 2-<12 Years Old), with Venous Thromboembolism

Jacqueline ML Halton, MD, Manuela Albisetti, MD, Matteo Luciani, Fenglei Huang, Branislav Biss, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Lesley G Mitchell

Blood (2016) 128 (22): 87.

https://doi.org/10.1182/blood.V128.22.87.87

Published: 2016

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Jacqueline ML Halton, MD, Anne-Caroline Picard, Ruth Harper, Fenglei Huang, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Ildar Nurmeev, Lesley G Mitchell, Leonardo R. Brandão, MD MSc, Manuela Albisetti, MD

Blood (2016) 128 (22): 1441.

https://doi.org/10.1182/blood.V128.22.1441.1441

Published: 2016

Journal Articles

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Manuela Albisetti, MD, Arno Schlosser, MSc, Martina Brueckmann, MD, Savion Gropper, MD, Stephan Glund, PhD, Igor Tartakovsky, MD, Leonardo R. Brandão, MD MSc, Paul A Reilly, PhD

Blood (2016) 128 (22): 5010.

https://doi.org/10.1182/blood.V128.22.5010.5010

Published: 2016

Journal Articles

Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

Matteo Luciani, Manuela Albisetti, MD, Ivan Manastirski, Martina Brueckmann, MD, Savion Gropper, MD, Igor Tartakovsky, MD, Bushi Wang, Branislav Biss, Lesley G Mitchell, Fenglei Huang, Jacqueline ML Halton, MD, Leonardo R. Brandão, MD MSc

Blood (2016) 128 (22): 5028.

https://doi.org/10.1182/blood.V128.22.5028.5028

Published: 2016

Journal Articles

Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

Joanne van Ryn, PhD, Masahiro Yasaka, MD PhD, Ippei Ikushima, MD PhD, Akiko Harada, PhD, Atsushi Taniguchi, MSc, Susumu Imazu, PhD, Stephen Norris, PhD, Dietmar Gansser, PhD, Joachim Stangier, PhD

Blood (2016) 128 (22): 2627.

https://doi.org/10.1182/blood.V128.22.2627.2627

Published: 2016

Journal Articles

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

Stephan Glund, Joachim Stangier, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Gansser, Stephen Norris, Benjamin Lang, Paul Reilly, MD

Blood (2014) 124 (21): 344.

https://doi.org/10.1182/blood.V124.21.344.344

Published: 2014

Journal Articles

Impact of Apixaban On a Large Panel of Routine or More Specific Coagulation Assays.

Jonathan Douxfils, François Mullier, Christian Chatelain, Bernard Chatelain, Dogné Jean-Michel

Blood (2012) 120 (21): 2275.

https://doi.org/10.1182/blood.V120.21.2275.2275

Published: 2012

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a New Direct Thrombin Inhibitor (DPOC-4088) After Single Oral Doses of Two Prolonged Release Formulations in Healthy Male Subjects,

Luc M Van Bortel, Griet Van Lancker, Henri Vanden Bavière, Willem Hettema, Edwin Spaans, Sankar Ramakrishnan, Venkatesan Elumalai, Suryakumar Jayanthi, Stephane E Allard

Blood (2011) 118 (21): 3351.

https://doi.org/10.1182/blood.V118.21.3351.3351

Published: 2011

Journal Articles

Comparison of Laboratory Assays to Measure Rivaroxaban and Dabigatran

Severine Robert, François Mullier, Hassan Mekouar, Florence Polet, Jonathan Douxfils, Françoise Biot, Marie-Christine Lambert, Justine Baudar, Philippe Devel, Christian J. Chatelain, Bernard Chatelain, Jean-Michel Dogné

Blood (2010) 116 (21): 3332.

https://doi.org/10.1182/blood.V116.21.3332.3332

Published: 2010

Journal Articles

EP42675, a New Dual Action Anticoagulant: Pharmacodynamic and Pharmacokinetic Profile, and Interactions with Acetylsalicylic Acid, Clopidogrel, and Unfractionated Heparin.

Pierre Gueret, Chantal Krezel, Paul van Giersbergen, Eliane Fuseau, Thierry Lamy, Eric Neuhart

Blood (2009) 114 (22): 2090.

https://doi.org/10.1182/blood.V114.22.2090.2090

Published: 2009

Journal Articles

Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions

Jawed Fareed, Ph.D., Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Cafer Adiguzel, MD, Omer Iqbal, MD, Jeanine M. Walenga, PhD

Blood (2008) 112 (11): 4048.

https://doi.org/10.1182/blood.V112.11.4048.4048

Published: 2008

Journal Articles

Platelets and Heparin Induced Thrombocytopenia Antibodies Do Not Influence the Inhibitory Activity of Argatroban on Thrombin Generation.

Grigoris T. Gerotziafas, MD, PhD, Marie-Paule Roman, Elisabeth Verdy, MD, PhD, Mohamed Hatmi, PhD, Meyer M. Samama, Ismail Elalamy, MD, PhD

Blood (2007) 110 (11): 929.

https://doi.org/10.1182/blood.V110.11.929.929

Published: 2007

Journal Articles

The Effect of BIBT 986, a Novel Small Molecule Dual Inhibitor of Thrombin and Factor Xa, on Coagulation in a Model of Endotoxin Induced, Tissue Factor Triggered Coagulation Activation in Humans.

Bernd Jilma, MD, Judith M. Leitner, MD, Francesco Cardona, MD, Florian B. Mayr, MD, Christa Firbas, MD, Karin Rathgen, MD, Hildegard Staehle, PhD, Uwe Schuehly, MD, Eva U. Graefe-Mody, PhD

Blood (2006) 108 (11): 912.

https://doi.org/10.1182/blood.V108.11.912.912

Published: 2006

Journal Articles

Comparison of Activated Partial Thromboplastin Time Ratios with Ecarin Clotting Time Ratios for Monitoring Direct Thrombin Inhibitor Therapy: In-Vitro Study and Case Study of Lepirudin Therapy.

Harry L. Messmore, MD, Nancy J. Fabbrini, BS, Ketty Badrinath, MD, Richard Harriman, MD, Omar Iqbal, MD, Mary Lourdes Bird, MD

Blood (2005) 106 (11): 4149.

https://doi.org/10.1182/blood.V106.11.4149.4149

Published: 2005

Journal Articles

Assessment of Heparins, Heparinoids and Direct Thrombin Inhibitors Using a New FXa-and RVV-V-Based Assay.

Andreas Calatzis, MD, Armin J. Reininger, MD, Michael Spannagl, MD

Blood (2004) 104 (11): 1856.

https://doi.org/10.1182/blood.V104.11.1856.1856

Published: 2004

Journal Articles

Development of Prothrombinase Induced Clotting Time (Pefakit ®, PiCT) Assay and its Validation in the Monitoring of Anti-Xa and Anti-FIIa Drugs.

Debra A. Hoppensteadt, Ph.D., Josephine Cunanan, Jeanine M. Walenga, Ph.D., Jawed Fareed, Ph.D.

Blood (2004) 104 (11): 1858.

https://doi.org/10.1182/blood.V104.11.1858.1858

Published: 2004

NARROW

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children (Two Age Groups: 1-<2 and 2-<12 Years Old), with Venous Thromboembolism

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

Impact of Apixaban On a Large Panel of Routine or More Specific Coagulation Assays.

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a New Direct Thrombin Inhibitor (DPOC-4088) After Single Oral Doses of Two Prolonged Release Formulations in Healthy Male Subjects,

Comparison of Laboratory Assays to Measure Rivaroxaban and Dabigatran

EP42675, a New Dual Action Anticoagulant: Pharmacodynamic and Pharmacokinetic Profile, and Interactions with Acetylsalicylic Acid, Clopidogrel, and Unfractionated Heparin.

Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions

Platelets and Heparin Induced Thrombocytopenia Antibodies Do Not Influence the Inhibitory Activity of Argatroban on Thrombin Generation.

The Effect of BIBT 986, a Novel Small Molecule Dual Inhibitor of Thrombin and Factor Xa, on Coagulation in a Model of Endotoxin Induced, Tissue Factor Triggered Coagulation Activation in Humans.

Comparison of Activated Partial Thromboplastin Time Ratios with Ecarin Clotting Time Ratios for Monitoring Direct Thrombin Inhibitor Therapy: In-Vitro Study and Case Study of Lepirudin Therapy.

Assessment of Heparins, Heparinoids and Direct Thrombin Inhibitors Using a New FXa-and RVV-V-Based Assay.

Development of Prothrombinase Induced Clotting Time (Pefakit ®, PiCT) Assay and its Validation in the Monitoring of Anti-Xa and Anti-FIIa Drugs.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only